Accro Bioscience, a biotechnology company, has entered into an agreement granting Fosun Pharma exclusive rights to develop, manufacture, and commercialize its TYK2/JAK1 inhibitor, AC-201, in Greater China, encompassing Chinese Mainland, Hong Kong SAR, and Macau SAR. Accro will retain global rights for AC-201 outside these regions.
Under the terms of the deal, Accro will receive an upfront payment of RMB 60 million and a milestone payment of RMB 20 million upon completion of manufacturing technology transfer, totaling RMB 80 million. Additionally, Accro is eligible for up to RMB 76 million in development milestone payments, along with commercial milestone payments and tiered royalties reaching double-digit percentages based on sales in the licensed territories.
.png)
